文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹药疹与重症皮肤不良反应

皮肤科靶向治疗矛盾性皮疹的系统综述与分析

Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis.
PubMed 文献 · J Am Acad Dermatol · 2020-12-08

该系统综述分析了细胞因子靶向抗体(TNF-α、IL-12/23 p40、IL-17A/17R、IL-23 p19、IL-4Rα抑制剂)在皮肤科诱发的矛盾性皮疹。共纳入313篇文章、2049例病例,TNF-α抑制剂占91.2%(1869/2049),银屑病样和湿疹样皮疹最常见,停药后多可改善或消退。

要点

  • TNF-α抑制剂是矛盾性皮疹最常见诱因,占91.2%(1869/2049)。
  • 银屑病样和湿疹样皮疹为最常见表型,但表现谱广泛且可重叠。
  • 起病通常为数周至数月,也可超过1年后出现;停药后常改善或消退。

核心结论

  • 熟悉细胞因子阻断抗体所致矛盾性皮疹的临床特征,有助于高效识别和管理。

研究设计与样本

  • 系统综述与分析,检索已发表的与TNF-α、IL-12/23(p40)、IL-17A/17R、IL-23(p19)及IL-4Rα抑制剂相关的皮肤矛盾性反应病例。
  • 共纳入313篇文章、2049例矛盾性皮疹病例。

主要发现

  • TNF-α抑制剂占全部病例的91.2%(1869/2049),其次为IL-17/17R(3.5%)、IL-4Rα(2.7%)、IL-12/23(2.4%)和IL-23(0.01%)抑制剂。
  • 银屑病样和湿疹样皮疹是最常报告的类型,但描述了广泛的皮疹模式。
  • 表型重叠的反应模式常见。
  • 起病时间通常为数周至数月,但也可在超过1年后发生。
  • 停用诱因药物后改善或消退常见。

临床怎么用

  • 识别细胞因子靶向抗体治疗中出现的银屑病样或湿疹样皮疹等矛盾性反应,考虑停药后多可改善或消退。

局限性

  • 本研究为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibody-based therapies that inhibit proinflammatory cytokine signaling are commonly used in dermatology. Paradoxically, these medications may induce or exacerbate inflammatory disorders. OBJECTIVE: To summarize the spectrum of manifestations, incidence, timing, potential mechanisms of, and general management approaches to paradoxical cutaneous reactions induced by cytokine-targeted antibodies in dermatology. METHODS: We performed a systematic review and analysis of published cases of cutaneous paradoxical reactions (PRs) reported in association with tumor necrosis factor α, interleukin (IL) 12/23 (p40), IL-17A/17R, IL-23 (p19), and IL-4Rα inhibitors. RESULTS: We identified 313 articles reporting 2049 cases of PRs. Tumor necrosis factor α inhibitors resulted in 91.2% (1869/2049) of all cases, followed by IL-17/17R (3.5%), IL-4Rα (2.7%), IL-12/23 (2.4%), and IL-23 (0.01%) inhibitors. Psoriasiform and eczematous eruptions were the most commonly reported, but a wide spectrum of patterns were described. Phenotypically overlapping reaction patterns were common. Time to onset typically ranged from weeks to months but could occur more than a year later. Improvement or resolution upon discontinuation of the inciting drug was common. LIMITATIONS: This was a retrospective analysis. CONCLUSIONS: Familiarity with the clinical features of PRs from cytokine-blocking antibodies may facilitate efficient recognition and management.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol. 2020. PMID: 33307146. doi:10.1016/j.jaad.2020.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。